List of Orilissa drug patents

Orilissa is owned by Abbvie Inc.

Orilissa contains Elagolix Sodium.

Orilissa has a total of 6 drug patents out of which 0 drug patents have expired.

Orilissa was authorised for market use on 23 July, 2018.

Orilissa is available in tablet;oral dosage forms.

Orilissa can be used as management of moderate to severe pain associated with endometriosis using 150mg elagolix while co-administering rifampin, management of moderate to severe pain associated with endometriosis, use of elagolix 200 mg bid for 6 months to manage moderate to severe pain associated with endometriosis in premenopausal women to reduce dysmenorrhea and non-menstrual pelvic pain; use of elagolix 200 mg bid for 6 months to manage moderate to severe pain associated with endometriosis in premenopausal women having dyspareunia associated with endometriosis, management of moderate to severe pain associated with endometriosis using 150 mg elagolix while co-administering ketoconazole.

Drug patent challenges can be filed against Orilissa from July, 2022.

The generics of Orilissa are possible to be released after 01 September, 2036.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7419983 ABBVIE INC Gonadotropin-releasing hormone receptor antagonists and methods related thereto
Jul, 2024

(1 year, 4 months from now)

US7056927 ABBVIE INC Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
Sep, 2024

(1 year, 7 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7176211 ABBVIE INC Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
Jul, 2024

(1 year, 4 months from now)

US11344551 ABBVIE INC Methods of treating heavy menstrual bleeding
Mar, 2034

(11 years from now)

US10537572 ABBVIE INC Methods of administering elagolix
Sep, 2036

(13 years from now)

US10682351 ABBVIE INC Methods of administering elagolix
Sep, 2036

(13 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 23, 2023

Drugs and Companies using ELAGOLIX SODIUM ingredient

NCE-1 date: July, 2022

Market Authorisation Date: 23 July, 2018

Treatment: Management of moderate to severe pain associated with endometriosis; Use of elagolix 200 mg bid for 6 months to manage moderate to severe pain associated with endometriosis in premenopausal women to reduce dysmenorrhea and non-menstrual pelvic pain; Use of elagolix 200 mg bid for 6 months to manage moderate to severe pain associated with endometriosis in premenopausal women having dyspareunia associated with endometriosis; Management of moderate to severe pain associated with endometriosis using 150mg elagolix while co-administering rifampin; Management of moderate to severe pain associated with endometriosis using 150 mg elagolix while co-administering ketoconazole

Dosage: TABLET;ORAL

How can I launch a generic of ORILISSA before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in